Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AlloVax in refractory HCC
NCT01995227Phase 2Withdrawn
- Sponsor
- Mirror Biologics, Inc.
- Start
- Dec 2013
- Primary completion
- Feb 2018
- Modality
- Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of AlloVax in hepatocellular carcinoma (HCC), sponsored by Mirror Biologics, Inc. Primary endpoint: Safety at 30 days. Planned start Dec 2013; status: withdrawn.
02
Drugs
AlloVax
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01995227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01995227.